

**P&T Motion History**  
**Diabetes Drugs – DPP-4 Inhibitors**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
alogliptin linagliptan saxagliptin sitagliptin	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Diabetes, I move that DPP-4 inhibitors linagliptan, saxagliptin, alogliptin, and sitagliptin are safe and efficacious.</p> <p>DPP-4 inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Therapeutic interchange is allowed only within each Diabetes subclass.</p> <p>Motion: Smith            2<sup>nd</sup>: Wiser</p>	October 19, 2016	NA	Yes Harvey Johnson	Passed unanimous